Drugs / RTS,S/AS01E
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03276962 | Sep 2017 → Nov 2019 | malaria | GlaxoSmithKline | Completed | Missed primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-10-06 | GlaxoSmithKline | GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine gsk.com ↗ |
| 2021-01-27 | GlaxoSmithKline | GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine gsk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTS,S/AS01(E) | “Efficacy of RTS,S/AS01(E) malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in...” PMID 35753316 ↗ Jun 2022 |
| Known as | RTS,S | “the RTS,S/AS01E vaccine (RTS,S)” PMID 40975080 ↗ Oct 2025 |
| Modality | Vaccine | “the RTS,S/AS01E vaccine” NCT03276962 ↗ |
| Route | Intramuscular | “All vaccines were administered by intramuscular injection in the left deltoid.” PMID 35753316 ↗ Jun 2022 |